<DOC>
	<DOCNO>NCT02632526</DOCNO>
	<brief_summary>This phase I , randomise , single-blind , placebo-controlled , first-in-human ( FIH ) single multiple ascend dose study consist two part ( Part A [ SAD ] Part B [ MAD ] ) ass safety , tolerability , pharmacokinetics pharmacodynamics AZD5718 healthy male subject</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability , Pharmacokinetics Pharmacodynamics AZD5718 After Single Multiple Ascending Dose Administration Healthy Male Subjects</brief_title>
	<detailed_description>This phase I , randomise , single-blind , placebo-controlled , first-in-human ( FIH ) single multiple ascend dose study consist two part ( Part A [ SAD ] Part B [ MAD ] ) ass safety , tolerability , pharmacokinetics pharmacodynamics AZD5718 healthy male subject</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>1 . Provision sign date , write informed consent prior study specific procedures 2 . Healthy male subject age 18 50 year , inclusive , suitable vein cannulation repeat venepuncture 3 . Have body mass index ( BMI ) 18 30 kg/m2 inclusive weigh least 50 kg 100 kg inclusive 4 . Provision sign , write date informed consent optional genetic research 1 . History clinically significant disease disorder , opinion Investigator , may either put subject risk participation study , influence result subject 's ability participate study 2 . History presence gastrointestinal ( GI ) , hepatic renal disease , condition know interfere absorption , distribution , metabolism , excretion drug 3 . Any clinically significant illness , medical/surgical procedure , trauma within 4 week administration investigational medicinal product ( IMP ) 4 . Any clinically significant abnormality clinical chemistry , haematology , urinalysis result screen checkin , judge investigator , include : Alanine aminotransferase ( ALT ) &gt; upper limit normal ( ULN ) ; Aspartate aminotransferase ( AST ) &gt; ULN ; Bilirubin ( total ) &gt; ULN ; Gamma glutamyl transpeptidase ( GGT ) &gt; ULN 5 . Any positive result screen serum hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody human immunodeficiency virus ( HIV ) 6 . Suspicion know Gilbert 's syndrome 7 . Abnormal vital sign , 10 minute supine rest , screen checkin , define follow : Systolic blood pressure ( BP ) ( SBP ) &lt; 90mmHg ≥ 140 mmHg ; Diastolic BP ( DBP ) &lt; 50mmHg ≥ 90 mmHg ; Pulse &lt; 45 &gt; 85 beat per minute ( bpm ) 8 . Any clinically significant abnormality ( screen checkin ) rhythm , conduction morphology rest ECG clinically significant abnormality 12lead ECG , consider investigator may interfere interpretation QTc interval change , include abnormal STTwave morphology , particularly protocol define primary lead leave ventricular hypertrophy 9 . Prolonged QTcF ( QT interval correct heart rate use Fridericia 's formula ) &gt; 450 m shorten QTcF &lt; 340 m family history long QT syndrome , screen checkin 10 . PR ( PQ ) interval ( ECG interval measure onset P wave onset QRS complex ) shorten &lt; 120 m ( PR &gt; 110 m &lt; 120 m acceptable evidence ventricular preexcitation ) , screen checkin 11 . PR ( PQ ) interval prolongation ( &gt; 240 m ) intermittent second ( Wenckebach block asleep exclusive ) third degree AV block , AV dissociation , screen checkin 12 . Persistent intermittent complete bundle branch block ( BBB ) , incomplete bundle branch block ( IBBB ) , intraventricular conduction delay ( IVCD ) QRS &gt; 110 m . Subjects QRS &gt; 110 m &lt; 115 m acceptable evidence , example , ventricular hypertrophy preexcitation , screen checkin 13 . Known suspected history drug abuse , judge investigator 14 . Current smoker smoke used nicotine product within 3 month prior screen 15 . Any history alcohol abuse excessive intake alcohol , judge investigator 16 . Positive screen drug abuse , alcohol cotinine ( nicotine ) screen admission unit 17 . History severe allergy/hypersensitivity ongoing clinically significant allergy/hypersensitivity , judge investigator history hypersensitivity drug similar chemical structure class AZD5718 18 . Excessive intake caffeine contain drink food ( e.g. , coffee , tea , chocolate ) , judge investigator 19 . Use drug enzyme induce property St John 's Wort within 3 week prior first administration IMP 20 . Use prescribed nonprescribed medication include antacid , analgesic ( paracetamol/acetaminophen ) , herbal remedy , megadose vitamin ( intake 20 600 time recommended daily dose ) mineral 2 week prior administration IMP long medication long halflife 21 . Plasma donation within 1 month screen blood donation/blood loss &gt; 500 mL 3 month prior screen 22 . Has receive another new chemical entity ( define compound approve marketing ) within 3 month administration IMP study . The period exclusion 3 month final dose previous study 23 . Vulnerable subject , e.g. , keep detention , protect adult guardianship , trusteeship , committed institution governmental juridical order 24 . Involvement AstraZeneca , PAREXEL study site employee close relatives 25 . Judgment investigator subject participate study ongoing recent ( i.e. , screen period ) minor medical complaint may interfere interpretation study data consider unlikely comply study procedure , restriction requirement 26 . Subjects vegans medical dietary restriction 27 . Subjects communicate reliably investigator In addition , follow regarded criterion exclusion genetic research : 28 . Previous bone marrow transplant 29 . Nonleukocyte deplete whole blood transfusion within 120 day date genetic sample collection</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>AZD5718 oral suspension crystalline</keyword>
	<keyword>AZD5718 oral suspension amorphous</keyword>
	<keyword>Single ascend dose/multiple ascend dose ( SAD/MAD )</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>